Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
BeerYaakov Mental Health Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00708396CT.gov Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study | — | Unknown | — | — | — |
NCT00374348CT.gov Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obsessive-Compulsive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Escitalopram (this asset) | BeerYaakov Mental Health Center | Approved | BB · 65 |
| Fluoxetine | Massachusetts General Hospital | P4 | BB |
| Sertraline | Yang I. Pachankis, PhD | P4 | BB |
| Rituximab | Uppsala University Hospital | P2 | CCC |
| Clomipramine | National Center for Research Resources (NCRR) | P2 | CCC |
| Paroxetine | Beijing Tongren Hospital | P1 | CC |
| Teonanacatl | Yale University | P1 | CC |
| Jnj-54135419 | Mark Niciu | Unk | D |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Medical University of Gdansk | Unk | D |
+2 more in the Obsessive-Compulsive Disorder cohort
Other indications for Escitalopram
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 77 |
| Dysthymic Disorder | — | P4 | BBB · 76 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Escitalopram in Obsessive-Compulsive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/escitalopram-obsessive-compulsive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →